

OCT 06 2003

Express Mail No.: EV335857137US

Sheet 1 of 2

LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY DOCKET NO.

10034-004-999

APPLICATION NO

10/067,146

APPLICANT

Siegal et al.

FILING DATE

February 4, 2002

GROUP

1636

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
R	A01	5,676,942	10/14/97	Testa et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
							YES NO

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

R	C01	Abb et al., 1983, "Phenotype of human alpha-interferon producing leucocytes identified by monoclonal antibodies," Clin Exp Immunol. 52(1):179-84
R	C02	Autran et al., 1997, "Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease," Science 277(5322):112-6
R	C03	Bandyopadhyay et al., 1986, "Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts," J Exp Med. 164(1):180-95
R	C04	Brinkmann et al., 1993, "Interferon alpha increases the frequency of interferon gamma-producing human CD4+ T cells," J Exp Med. 178(5):1655-63
R	C05	Bubenik, 1996, "Cytokine Gene-Modified Vaccines in the Therapy of Cancer," Pharmacol. Ther. 69(1):1-14
R	C06	Cederblad et al., 1991, "Interferons and the colony-stimulating factors IL-3 and GM-CSF enhance the IFN-alpha response in human blood leucocytes induced by herpes simplex virus," Scand J Immunol. 1991 Nov;34(5):549-55
R	C07	Chehimi et al., 1989, "Dendritic cells and IFN-alpha-producing cells are two functionally distinct non-B, non-monocytic HLA-DR+ cell subsets in human peripheral blood," Immunology 68(4):488-90
R	C08	Clerici et al., 1994, "The Th1-Th2 hypothesis of HIV infection: new insights," Immunol Today 15(12):575-81 Review
R	C09	Dong et al., 1999, Cancer Res. 59:872-879
R	C10	Eck et al., 1996, "Gene-Based Therapy," Pharmacological Basis of Therapeutics, Chapter 5: 77-101
R	C11	Empson et al., 1999, "Atopy, anergic status, and cytokine expression in HIV-infected subjects," J Allergy Clin Immunol. 103(5 Pt 1):833-42
R	C12	Feldman et al., 1995, J. Leuk. Biol. 57:214-220
R	C13	Feldman et al., 1994, Virology 204:1-7
R	C14	Feldman et al., 1990, J. Interferon Res. 10:435-446
R	C15	Ferbas et al., 1995, Clin. Diagn. Lab. Immunol. 2:138-142
R	C16	Ferbas et al., 1994, J. Immunol. 152:4649-4662
R	C17	Fitzgerald-Bocarsly, 1993, Pharmacol. Ther. 60:39-62
R	C18	Fitzgerald-Bocarsly, 1988, J. Leuk. Biol. 43:323-334
R	C19	Ghanekar et al., 1996, J. Immunol. 157:4028-4036
R	C20	Grouard et al., 1997, J. Exp. Med. 185:1101-1111 (or Grouard)
R	C21	Harrison et al., 1997, J. Immunol. 158:459-463
R	C22	Howell et al., 1994, Clin. Immunol. Immunopathol. 71(2):223-230

NY2: 1467663.1

✓	C23	Isaacs et al., 1957, Proc. R. Soc. London 147:25B
✓	C24	Kirchner et al., 1979, Immunobiology 156:65-75
✓	C25	Komanduri et al., 1998, Nat. Med. 4:953-956
✓	C26	Kostense et al., 1998, AIDS 12:F235-240
✓	C27	Ledergerber et al., 1999, J. Amer. Med. Assn. 282:2220-2226
✓	C28	Lederman et al., 1998, J. Inf. Dis. 178:70-79
✓	C29	Ledley, 1991, Human Gene Therapy 2:77-83
✓	C30	Leigh et al., 1998, J. Acquir. Immune Def. Syndr. Hum. Retrovirol. 19:373-380
✓	C31	Lopez et al., 1983, J. Inf. Dis. 148:962-966
✓	C32	Marrack et al., 1999, J. Exp. Med. 189:52
✓	C33	Milone et al., 1998, J. Immunol. 161:2391-2399
✓	C34	Mocroft et al., 1998, Lancet 352:1725-1730
✓	C35	O'Doherty et al., 1994, Immunology 82:487
✓	C36	O'Doherty et al., 1993, J. Exp. Med. 178:1067
✓	C37	Olweus et al., 1997, PNAS USA 94:125551
✓	C38	Pakker et al., 1998, Nat. Med. 4:208-214
✓	C39	Palella et al., 1998, N. Engl. J. Med. 338:853-860
✓	C40	Parronchi et al., 1996, Eur. J. Immunol. 26:697-703
✓	C41	Payvandi et al., 1998, J. Immunol. 160:5861-5868
✓	C42	Perussia et al., 1985, Nat. Immunol. Cell Growth Regul. 4:120-137
✓	C43	Peter et al., 1980, Eur. J. Immunol. 10:547-555
✓	C44	Pontesilli et al., 1999, Immunol. Lett. 66:213-217
✓	C45	Powderly et al., 1998, J. Amer. Med. Assoc. 280:72-77
✓	C46	Qin et al., 1998, PNAS 95:14411-14416
✓	C47	Rappocciolo et al., 1989, J. Clin. Microbiol. 27:41-48
✓	C48	Rissoan et al., 1999, Science 283:1183-1186
✓	C49	Rogge et al., 1998, J. Immunol. 161:6567-6574
✓	C50	Sandberg et al., 1991, Scan. J. Immunol. 34:565-576
✓	C51	Sandberg et al., 1990, J. Immunol. 145:1015-1020
✓	C52	Sanhadji et al., 1997, AIDS 11:977-986
✓	C53	Schneider et al., 1999, Lancet 353:201-203
✓	C54	Shodell, M., FP Siegal: abstract submitted, FASEB AAI/CIS Congress, Seattle, WA, May, 2000
✓	C55	Siegal et al., 1999, Science 284:1835-1837
✓	C56	Siegal et al., 1994, Leukemia 8:1474-1479
✓	C57	Siegal et al., 1986, J. Clin. Invest. 78:115-123
✓	C58	Starr et al., 1993, Adv. Exp. Med. Biol. 329:173-178
✓	C59	Sun et al., 1998, J. Exp. Med. 188:2335
✓	C60	Svensson et al., 1996, J. Interferon Cytok. Res. 16:7-16
✓	C61	Svensson et al., 1996, Scan. J. Immunol. 44:164-172
✓	C62	Viellard et al., 1997, PNAS 94:11595-11600

EXAMINER

Sumner

DATE CONSIDERED

11/12/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.